NCT01260753

Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Palau Pharma S.L.U. · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to explore the activity of UR-63325 in a model of allergic rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise healthy.

Conditions

• Seasonal Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	UR-63325	UR-63325
DRUG	Fluticasone propionate nasal spray	Fluticasone propionate nasal spray
DRUG	Placebo	Placebo to UR 63325 and fluticasone propionate nasal spray

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-03-01
• Completion: 2011-03-01
• First posted: 2010-12-15
• Last updated: 2011-04-15

Locations

1 site across 1 country: Germany